Latest Ratios: P/E Ratio -8.3x · EV/EBITDA N/A · ROE -219.0%. (2012–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.0B | $171M | $69M | $53M | $67M | $83M | $115M | $61M | $119M | $151M | $236M |
| Enterprise Value | $6.8B | $-15570919 | $39M | $21M | $9M | $55M | $76M | $-3838701 | $54M | $56M | $129M |
| P/E Ratio → | -8.28 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 5460.07 | 133.87 | 2.98 | 0.82 | 1.34 | 6.89 | 5.50 | — | — | — | — |
| P/B Ratio | 8.61 | 1.05 | — | — | 3.09 | 7.76 | 3.04 | 1.03 | 1.99 | 1.71 | 2.27 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -12.21 | 1.65 | 0.33 | 0.19 | 4.57 | 3.65 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -57.9% | 100.0% | -47.4% | 100.0% | -121.9% | — | — | — | — |
| Operating Margin | -13811.9% | -13811.9% | -116.2% | -52.0% | -85.2% | -595.4% | -199.5% | — | — | — | — |
| Net Profit Margin | -13319.8% | -13319.8% | -98.5% | -52.1% | -85.7% | -597.6% | -196.5% | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -219.0% | -219.0% | — | -941.4% | -263.1% | -297.1% | -84.7% | -99.3% | -75.3% | -50.1% | -51.5% |
| ROA | -120.5% | -120.5% | -40.0% | -54.7% | -62.6% | -111.5% | -55.5% | -74.6% | -59.9% | -44.4% | -47.9% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -213.6% | -213.6% | -949.6% | -141.4% | -133.8% | -237.0% | -85.2% | -100.3% | -67.5% | -47.9% | -51.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | — | — | 0.23 | 0.74 | 0.31 | 0.17 | 0.17 | 0.11 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.14 | — | — | -2.65 | -2.61 | -1.02 | -1.09 | -1.10 | -1.08 | -1.03 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -274.23 | — | -100.61 | -7960.14 | -178.73 | -269.27 |
Net cash position: cash ($190M) exceeds total debt ($4M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.25 | 4.25 | 0.90 | 1.09 | 2.11 | 1.48 | 2.18 | 3.88 | 6.43 | 11.83 | 18.11 |
| Quick Ratio | 4.25 | 4.25 | 0.81 | 1.09 | 2.18 | 1.48 | 2.18 | 3.88 | 6.45 | 11.83 | 18.11 |
| Cash Ratio | 3.83 | 3.83 | 0.53 | 0.79 | 1.83 | 0.93 | 1.66 | 3.75 | 6.23 | 11.74 | 18.00 |
| Asset Turnover | — | 0.01 | 0.35 | 1.36 | 0.66 | 0.20 | 0.30 | — | — | — | — |
| Inventory Turnover | 6.03 | — | 6.03 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 484.95 | 254.68 | 33.04 | 39.44 | 338.02 | 0.17 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $4M | $3M | $3M | $2M | $1M | $1M | $875043 | $724449 | $688484 |
Clinical trial milestone dependency
As reported in recent financial filings, CDTX trades at a price-to-book ratio of 8.61, which suggests that investors are assigning a significant premium to the company's intellectual property and R&D platform despite the absence of recurring revenue or positive earnings to support traditional valuation multiples.
The extreme P/S ratio of over 5,000x highlights the market's focus on future clinical potential rather than current operational performance. Investors should monitor whether this valuation premium holds as the company moves through expensive late-stage trials, as any delay in milestone achievement could lead to a sharp re-rating of the stock.
Based on the company's reported figures, the ROIC of -107.5% in 2025Q3 underscores the significant capital destruction inherent in the current clinical-stage business model, where massive R&D spending is required to validate the Cloudbreak platform before any potential for sustainable capital compounding can be realized.
The persistent negative ROE and ROIC trends indicate that the company is currently a value-consuming entity rather than a value-creating one. This performance is typical for biotech firms in the pre-commercial phase, but it warrants further investigation into whether the platform's eventual commercialization can generate returns that exceed the cost of capital.
According to recent balance sheet data, the company maintains a current ratio of 4.62 as of 2025Q3, which provides a substantial liquidity cushion that appears sufficient to fund ongoing research activities and clinical trials without the immediate necessity of accessing dilutive capital markets in the near term.
The high liquidity position is a critical safeguard against the volatility of milestone-based revenue. However, investors should remain cautious, as the rapid burn rate associated with Phase 3 trials could quickly erode this buffer if clinical timelines are extended or if partnership funding fails to materialize as expected.
As noted in financial analysis literature, the use of P/E ratios for clinical-stage biotechs like CDTX is fundamentally flawed, as these metrics obscure the company's true value driver, which is the probability-weighted net present value of its pipeline rather than current accounting earnings or operational margins.
Analysts should instead focus on cash runway and clinical milestone probability, as traditional profitability metrics like net margin are rendered meaningless by the lumpy nature of licensing revenue. Relying on P/E or EBITDA multiples in this context may lead to incorrect conclusions regarding the company's long-term financial health and investment viability.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CDTX stock.
Cidara Therapeutics, Inc.'s current P/E ratio is -8.3x. This places it at the 50th percentile of its historical range.
Cidara Therapeutics, Inc.'s return on equity (ROE) is -219.0%. The historical average is -140.1%.
Based on historical data, Cidara Therapeutics, Inc. is trading at a P/E of -8.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Cidara Therapeutics, Inc. has 100.0% gross margin and -13811.9% operating margin.